Verily vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $300M (Mar 2026) led by Series X Capital. Became independent corporation; Alphabet now minority investor. Partners include Samsung Galaxy Watch 8 and Salesforce.
About
Verily is a precision health AI company that became independent from Alphabet (Google's parent) in March 2026 when it raised $300 million led by Series X Capital, transitioning Alphabet to a minority investor. The independence marks a major strategic inflection: Verily now competes as a standalone health AI platform rather than operating as a Google moonshot project, with the commercial accountability that comes with external capital and institutional investors.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.